Posts Tagged ‘Survival’

Mesothelioma Prognosis – Life Expectancy & Survival Rates

Mesothelioma Prognosis – Life Expectancy & Survival Rates

The term prognosis is used to describe the likely outcome of a disease, how long a diagnosed patient is expected to live, and the quality of life expected during that time.  This article discusses the prognosis for mesothelioma patients affected on a multitude of levels.

Once a patient is diagnosed, a doctor will likely discuss their prognosis, or probable course and outcome of the cancer’s influence on the body.  The best way to avoid a poor prognosis is through early detection.  As a result, the prognosis for the majority of patients is poor, but many doctors can recommend treatment options such as surgery, chemotherapy and radiation to help combat the disease. 

In addition to the stage of the cancer and the age of the patient, other factors that affect prognosis include: The type of mesothelioma – pleural, peritoneal, pericardial or testicular The size of the tumor, the location of the tumor, and whether it can be surgically removed, the extent of other symptoms, including fluid in the lungs or abdomen and whether or not the patient is a smoker. 

Though numerous factors affect a patient’s prognosis such as age, overall health, and the type of mesothelioma the patient is battling, the average length of survival reported throughout the last five years has been 10 to 11 months after diagnosis.  Early detection of pleural mesothelioma can improve a patient’s mesothelioma prognosis considerably, and these patients have more extensive treatment options. 

Patients diagnosed with pleural mesothelioma in stage one or two generally have greater treatment options and a better prognosis.  Pleural mesothelioma patients who are not diagnosed early enough for curative treatment have fewer treatment options, mostly limited to palliative treatments, designed to relieve pain and discomfort to improve a patient’s quality of life, rather than their prognosis. 

If a patient is diagnosed once the disease has reached the advanced stages, treatment options are limited and prognosis is often compromised.  A patient’s overall health status and age greatly affects the prognosis.  Cancer that has not metastasized to other areas of the body gives physicians a lot more treatment options and improves a patient’s prognosis dramatically. 

Pleural mesothelioma patients have a poorer prognosis if they are experiencing chest pain, shortness of breath, inability to perform daily tasks, weight loss, a low red blood cell count, a high white blood cell count, and high blood levels of a substance called LDH (lactate dehydrogenase, an enzyme).  Pleural mesothelioma patients who experience these symptoms usually receive a prognosis ranging between six and 12 months. 

The median survival of patients diagnosed with malignant mesothelioma from time of first dignosis is one year; in male patients or those with elevated white-cell counts, thrombocytosis or anemia, the prognosis is far worse.  The presence of certain biochemical markers, as well increased vascularity or the presence of the SV40 virus in the tumor, are other indicators that the prognosis would be more serious.  The fibrosarcomatus type carries the worst prognosis, while the mixed (a combination of both kinds) comes in between them.

However, many have overcome such a poor prognosis and have prolonged their life in a multitude of ways.    

Have you been affected by mesothelioma? Learn more at: Mesothelioma Disease Blog

Article from

More Mesothelioma Survival Rate Articles

Foods Said to Increase Survival Rate among Those Exposed to Asbestos

Foods Said to Increase Survival Rate among Those Exposed to Asbestos

Recently, a research paper authored by a group of investigators at the National Cancer Institute (NCI) and Louisiana State University, resurfaced providing details on individuals who have fallen victim to mesothelioma cancer based off of their dietary habits.
The report, which was compiled by a Diet and Mesothelioma taskforce, followed 116 individuals, half of whom had mesothelioma cancer and the other half had been exposed to asbestos but did not develop mesothelioma or other asbestos-related conditions. Both groups had similar incomes and tobacco usage as well as having comparable exposure to asbestos.
According to news reports, the researchers studied the foods consumed by both groups and found the following to be true of dietary habits:
* Individuals who remained cancer-free after exposure to asbestos were found to have eaten nearly twice the amount of locally/homegrown vegetables and fruits as those stricken with mesothelioma.
* Victims of mesothelioma ate more “cake, candy and pie than those who stayed cancer-free.”
* Those consuming what are known as cruciferous vegetables – such as mustard greens, collards, broccoli, turnip greens, cabbage or brussel sprouts – were likely to remain mesothelioma-free even after exposure to asbestos occurred.
While more research is likely needed to verify these results, scientists at the NCI are putting faith into these dietary guidelines. The NCI, the Centers for Disease Control and Prevention(CDC), Department of Health and Human Services and the U.S. Government have partnered together to create a campaign on the importance of eating vegetables and fruits to ensure a healthy lifestyle.
Foods to Improve Mesothelioma
The taskforce determined dietary habits had a role in the fight against cancer and several experts have also claimed this; eating certain types of foods, especially when organically grown, will likely decrease the chance of developing mesothelioma cancer for an individual who had endured asbestos exposure. The following are a list of foods found to be beneficial against deadly conditions such as asbestosis or mesothelioma.
* Olives, which contain maslinic and oleanolic acids can promote apoptosis – the death of cancer cells.
* Cabbage is high in glucosinolates (anticarcinogenic compounds), also raw cabbage contains substances to rid the body of carcinogens.
* Flaxseeds are filled with lignans and omega-3 fatty acids – potentially capable of lowering the risk of breast cancer in women and colon cancer among both sexes.
* Raspberries – most berries – are a source of fiber, vitamin C, ellagic acid and selenium.
* Mushrooms, which can block aromatase (breast cancer causing enzymes) and suppress the growth of prostate cancer cells.
* Pumpkin as well as carrots and winter squash all contain high levels of carotenoids and betacarotene.
* Onions contain phenolic compounds that are considered anticancer compounds.
What is Asbestos-Induced Mesothelioma?
Asbestos-induced mesothelioma is an incurable form of cancer that develops after fibrous tissue bundles containing tremolite are inhaled and begin to develop cancerous cells on the interior lining of the lungs. Asbestos largely went unregulated for decades while millions of U.S. citizens were at risk for exposure to this silent killer. It was mined from vermiculite and used as an alternative, less-costly and fire-retardant ingredient in insulation.
There are several variations of mesothelioma cancer with pleural malignant mesothelioma considered the most deadly and having the lowest survival rate.
Other Treatments for Increasing Mesothelioma Survival Rate
There are currently no treatments in existence that can cure mesothelioma cancer or any variation of the unfortunate disease. However, scientists and researchers are working continuously to find treatments to decrease the severity of an individual’s symptoms as well as increase the survival rate among victims.
Additionally, scientists keep studying the effects of certain foods and how it affects particular types of cancer. For example, researchers at the NIC within the Division of Cancer Control and Population Sciences (DCCPS) have created a research center, with funding, dedicated to the study of dietary intake and cancer. Another study, which was published in a January 2006 issue of Journal of The American Medical Association, looked at the relationship between consumption of large amounts of omega-3 fatty acids (like those found in fish) and breast, prostate and colorectal cancers.
The U.S. National Institutes of Health (NIH), funded and developed by the government, has developed resources for patients suffering from mesothelioma cancer in order for these individuals to have online access to the most up-to-date clinical trials. Ongoing information for a variety of clinical trials can be found at
However, individuals who may be suffering from mesothelioma cancer or any other asbestos-induced condition should not only seek medical attention for their symptoms, but are advised to locate a knowledgeable mesothelioma lawyer who may be able to provide insightful details of a mesothelioma lawsuit. By consulting with a mesothelioma attorney, the potential for being awarded monetary compensation for bills and damages becomes a reality.

Mesothelioma Life Expectancy-What are your chances of survival?

Mesothelioma Life Expectancy-What are your chances of survival?

About 2,000 to 3,000 new cases of mesothelioma is diagnosed every year in the United States of America. Mesothelioma is a rare form of cancer and it is an after effect of the asbestos exposure. The cancerous cells affect and destroy the mesothelium, which is a protective sac that holds the internal organs of the body. Initially, pleura or peritoneum are affected and then it spreads to the other parts of the body. It is a fatal disease and most victims do not survive beyond around one year after diagnosis, depending on the treatment and other contributing factors.

What is mesothelioma prognosis?

Prognosis for mesothelioma is dependent on the promptness of diagnosis and the treatment offered the victim. The earlier treatment is initiated the better the prognosis of the patient.

Also other factors that determine prognosis include the type of treatment, the histological {cellular type} type of mesothelioma as well as patient’s general state of health and morale. The stage of the disease during diagnosis is another crucial factor that decides the prognosis and the minimum survival expectancy of the victim.

Amongst the staging systems the oldest of them all is the Butchart system, based on the extent of mass, primary tumor and segregates the cancer into four stages. The TNM system is a more recent one while the Brigham system is the latest. It uses resectability and lymph node involvement for staging mesothelioma. Generally the higher the stage of the cancer the worse the prognosis of the victim. Sadly however most of the time diagnosis is made when the cancer is already in its advanced and latter stages, this is attributed to the long incubation period and the non specificity of the symptoms .

The traditional kinds of treatments are also prevalent in case of malignant mesothelioma include Radiation therapy which uses high-energy X-rays to eradicate cancer cells and chemotherapy which tries to destroy the cancer cells with the use of anticancer drugs.  Other forms of newer treatment options include Immunotherapy which helps to strengthen the immune system and photodynamic therapy that uses light energy while the genetic therapy resurrects the inherent genetic defects of the patient to fight the disease.

Surgery is also one of the traditional modes of treatment. There are different types of surgeries that are used: the process of removing fluid from the chest is known as thoracentesis while fluid reduction from the abdomen is known as paracentesis. The surgical removal of a part of the chest or the abdominal lining is called pleurectomy and if the lung is removed, then the operation will be termed as pneumonectomy.

When these treatment modalities are appropriately combined in the treatment of Mesothelioma especially in cases that are detected early, they can increase your 5 year life expectancy up to 10%.

Bello kamorudeen is the author of several mesothelioma articles.For complete information on mesothelioma visit

Article from

Mesothelioma Tumor Volumes and Survival Predictions

Mesothelioma Tumor Volumes and Survival Predictions

Another interesting study is called, “Preoperative Tumor Volume Is Associated With Outcome In Malignant Pleural Mesothelioma” by Harvey I. Pass, MD, Barbara K. Temeck, MD, Karen Kranda, RN, Seth M. Steinberg, PhD, Irwin R. Feuerstein, MD – From the Thoracic Oncology Section,a Biostatistics and Data Management Section,b National Cancer Institute, Diagnostic Radiology Department,c Warren Magnusen Clinical Center, National Institutes of Health, Bethesda, Md. GENERAL THORACIC SURGERY – J Thorac Cardiovasc Surg 1998;115:310-318.  Here is an excerpt: “Objectives: Our objective was to analyze the impact of preoperative and postresection solid tumor volumes on outcomes in 47 of 48 consecutive patients undergoing resection for malignant pleural mesothelioma who were treated prospectively and randomized to photodynamic therapy or no photodynamic therapy.   Methods: From July 1993 to June 1996, 48 patients with malignant pleural mesothelioma had cytoreductive debulking to 5 mm or less residual tumor by extrapleural pneumonectomy (n = 25) or leurectomy/decortication (n = 23). Three-dimensional computed tomographic reconstructions of preresection and postresection solid tumor were prospectively performed and the disease was staged postoperatively according to the new International Mesothelioma Interest Group staging.   Results: Median survival for all patients is 14.4 months (extrapleural pneumonectomy, 11 months; pleurectomy/decortication, 22 months; p2 = 0.07). Median survival for preoperative volume less than 100 was 22 months versus 11 months if more than 100 cc, p2 = 0.03. Median survival for postoperative volume less than 9 cc was 25 months versus 9 months if more than 9 cc, p2 = 0.0002. Thirty-two of forty-seven (68%) had positive N1 or N2 nodes. Tumor volumes associated with negative nodes were significantly smaller (median 51 cc) than those with positive nodes (median 166 cc, p2 = 0.01). Progressively higher stage was associated with higher median preoperative volume: stage I, 4 cc; stage II, 94 cc; stage III, 143 cc; stage IV, 505 cc; p2 = 0.007 for stage I versus II versus III versus IV. Patients with preoperative tumor volumes greater than 52 cc had shorter progression-free intervals (8 months) than those 51 cc or less (11 months; p2 = 0.02).  Conclusions: Preresection tumor volume is representative of T status in malignant pleural mesothelioma and can predict overall and progression-free survival, as well as postoperative stage. Large volumes are associated with nodal spread, and postresection residual tumor burden may predict outcome.” (J Thorac Cardiovasc Sufg 1998;115:310-8)

Another interesting study is called, “Use of a “Replication-Restricted” Herpes Virus to Treat Experimental Human Malignant Mesothelioma” by John C. Kucharczuk1, Bruce Randazzo1, Michael Y. Chang, Kunjlata M. Amin, Ashraf A. Elshami, Daniel H. Sterman, Nabil P. Rizk, Katherine L. Molnar-Kimber, S. Moira Brown, Alasdair R. MacLean, Leslie A. Litzky, Nigel W. Fraser, Steven M. Albelda, and Larry R. Kaiser – Cancer Res February 1, 1997 57; 466 – Here is an excerpt: “Abstract – Modified, nonneurovirulent herpes simplex viruses (HSVs) have shown promise in the treatment of brain tumors. However, HSV-1 can infect and lyse a wide range of cell types. In this report, we show that HSV-1716, a mutant lacking both copies of the gene coding ICP-34.5, can effectively treat a localized i.p. malignancy. Human malignant mesothelioma cells supported the growth of HSV-1716 and were efficiently lysed in vitro. i.p. injection of HSV-1716 into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy without dissemination or persistence after i.p. injection into SCID mice bearing human tumors. These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of nonneuronal origin such as malignant mesothelioma.

Another interesting study is called, “Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin” by Vernon J. Harvey MRCP, Dr. Maurice L. Slevin MRCP, Bruce A. J. Ponder PhD, MRCP, Anthony J. Blackshaw MA, MRCPath, Peter F. M. Wrigley PhD, FRCP – Cancer Volume 54, Issue 6, pages 961–964, 15 September 1984.  Here is an excerpt: “Abstract – Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single-agent Adriamycin (doxorubicin) after progression on 5-fluorouracil, and one partial response of 34 months was seen. It is concluded that 5-fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second-line agent.”

We all owe a debt of gratitude to these fine researchers for their work.  If you found any of these excerpts helpful, please read the studies in their entirety.


Monty Wrobleski is the author of this article.  For more information please click on the following links

Depuy Hip Recall

Mesothelioma Disease

Depuy Hip Recall

Article from

Survival Rate of Mesothelioma

Survival Rate of Mesothelioma

Individuals between the age group of 50 and 70 years are more likely to get the disease due to the long latency period. However, a survey conducted in 2007 revealed that the disease affects more people between the age group of 30 to 40. Based on industry and occupation, statistics indicate that people working in industries such as construction, railroad, shipyard, manufacturing and automobile industries are likely to be exposed to asbestos, with the construction industry having about 1.3 million people being exposed to asbestos.

The statistics on the study of mesothelioma also indicates that the life expectancy of people with the disease to be at least one year. However, with early detection and aggressive mesothelioma treatment, the life expectancy may increase up to two to five years. Studies also indicate mesothelioma can be a silent killer as the symptoms associate with the disease lies inactive in the body for very long periods ranging between ten to fifty years. As symptoms are likely to appear only in the later stages of the disease, this reduces the survival chances of the patient.

Mesothelioma Survival Rates

The disease is hard to detect as symptoms take the form of a simple upset stomach or simple breathlessness. As result, the disease is already in an advanced stage when finally diagnosed. This leaves them with just over a year left to live at this stage in spite of getting the best treatment possible.

Even though mesothelioma statistics have shown that it has been active over the past 100 years, records of the average survival rate of patients’ dates back to just 20 years. The study also revealed that the survival period for this type of cancer is within one to five years following a diagnosis. For those diagnosed between 1998 and 2002, the survival chance for these individuals is about 9%. Some of the factors that affects mesothelioma survival rate are:

The early detection of the disease The complexity of the disease Size of the tumor If the tumor can be removed via surgery The quantity of fluid in the chest or abdomen The age and general health of the patient The type of cancer cells

For the pleural and peritoneal mesothelioma, the survival rate is under a year. However, mesothelioma specialists believe that the survival period is longer despite findings derived via clinical trails. According to various medical literatures, the average survival rate is between 4 to 18 months. The survival rate for people diagnosed and treated in the earlier stages of the disease is not very clear and the timeframe can differ from person to person.

Mesothelioma Research

Extensive Mesothelioma research is undertaken by many organizations. Various companies using asbestos are also initiating their own research. This is because more and more people diagnosed with the disease are seeking compensation, and has resulted in these companies paying out huge amounts of money. The National Institute of Cancer is also conducting continuous mesothelioma research on the cause, symptoms, diagnosis as well as the cure and treatment of the disease.

Due the increase in demand for representation of patients seeking compensation, many law firms are also conducting their own research to understand more about the disease. Drug companies, research groups, and government organizations with the hope of bringing about a cure for the disease as well ways of increasing the survival rate among the patients usually provide funding for ongoing research.

Check this link

Article from

Epithelioid Mesothelioma and Asbestos Survival Statistics Our epithelioid Mesothelioma lawsuit expertise and wisdom can get you compensation. Our attorneys provide Mesothelioma support to those suffering from Asbestos lung cancer. Weve also acted in Mesothelioma class action suits. Kazan Law is a pioneer and a pillar in epithelioid Mesothelioma litigation. Visit or call 877.622.5246 today.
Video Rating: 0 / 5

Epithelioid Mesothelioma is a cancer whose only known cause is exposure to Asbestos. When fibers are inhaled, they can lodge in the cells of the Mesothelium, a membrane that lines the abdominal cavity, heart and lungs. Find out more about Epithelioid Mesothelioma at our website. If you have been exposed to Asbestos in the San Francisco area, call us today to review your case at 877.622.5246 or visit